CoChat

Mutant HRAS as novel target for MEK and mTOR inhibitors

Open access
Kiessling, Michael K., Curioni-Fontecedro, Alessandra, Samaras, Panagiotis, Atrott, Kirstin, Cosin-Roger, Jesus, Lang, Silvia, Scharl, Michael, Rogler, Gerhard · 2015 · Oncotarget
Cited by 56

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

// Michael K. Kiessling 1, 2 , Alessandra Curioni-Fontecedro 2 , Panagiotis Samaras 2 , Kirstin Atrott 1 , Jesus Cosin-Roger 3 , Silvia Lang 1 , Michael Scharl 1 , Gerhard Rogler 1 1 Division of Gastroenterology and Hepatology, University Hospital Zurich, and University of Zurich, Zurich, Switzerland 2 Division of Oncology, University Hospital Zurich, and University of Zurich, Zurich, Switzerland 3 Department of Pharmacology and CIBERehd, Faculty of Medicine, University of Valencia, Valencia, Spain Correspondence to: Michael K. Kiessling, e-mail: Michael.kiessling@usz.ch Keywords: HRAS mutations, MEK inhibitor, mTOR inhibitor, lung cancer, bladder cancer Received: March 23, 2015 Accepted: October 22, 2015 Published: November 03, 2015 ABSTRACT HRAS is a frequently mutated oncogene in cancer. However, mutant HRAS as drug target has not been investigated so far. Here, we show that mutant HRAS hyperactivates the RAS and the mTOR pathway in various cancer cell lines including lung, bladder and esophageal cancer. HRAS mutation sensitized toward growth inhibition by the MEK inhibitors AZD6244, MEK162 and PD0325901. Further, we found that MEK inhibitors induce apoptosis in mutant HRAS cell lines but not in cell lines lacking RAS mutations. In addition, knockdown of HRAS by siRNA blocked cell growth in mutant HRAS cell lines. Inhibition of the PI3K pathway alone or in combination with MEK inhibitors did not alter signaling nor had an impact on viability. However, inhibition of mTOR or combined inhibition of MEK and mTOR reduced cell growth in a synergistic manner. Finally, Ba/F3 cells transformed with mutant HRAS isoforms Q61L, Q61R and G12V demonstrated equal sensitivity towards MEK and mTOR inhibition. Our results show that HRAS mutations in cancer activate the RAS and mTOR pathways which might serve as a therapeutic option for patients with HRAS mutant tumors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.5619

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 56

Metadata

Authors
Kiessling, M. K., Curioni-Fontecedro, A., Samaras, P., Atrott, K., Cosin-Roger, J., Lang, S., Scharl, M., & Rogler, G.
Venue
Oncotarget
Published
2015-11-03
Volume
6
Issue
39
Pages
42183-42196
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2237484459
Cited by
56
References
10
FWCI
1.80
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mutant HRAS as novel target for MEK and mTOR inhibitors. https://app.cochat.ai/papers/10.18632/oncotarget.5619
The paper
Kiessling, M. K., Curioni-Fontecedro, A., Samaras, P., Atrott, K., Cosin-Roger, J., Lang, S., Scharl, M., & Rogler, G. (2015). Mutant HRAS as novel target for MEK and mTOR inhibitors. Oncotarget. https://doi.org/10.18632/oncotarget.5619

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.